A first-in-human study of RT011 for the treatment of dry age-related macular degeneration (AMD)
Latest Information Update: 22 Oct 2021
Price :
$35 *
At a glance
- Drugs Docosahexaenoic acid (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; First in man
- 19 Oct 2021 According to a Retrotope media release, the company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter.
- 02 Mar 2021 New trial record
- 11 Feb 2021 According to a Retrotope media release, the company expects to initiate this study in the mid-2021